Most patients with paraneoplastic encephalomyelitis/sensory neuronopathy PEM/SN have small-cell lung cancer (SCLC) and develop antibodies against neuronal-specific Hu proteins, which are abnormally expressed in the tumor. Anti-Hu reactivity is present in~16% of SCLC patients without PEM/SN. Here we test the hypothesis that engineered SCLC-prone mice may exhibit anti-Hu reactivity. We show that tumors from SCLC-prone mice misexpress Hu proteins, and 14% of mice harbor anti-Hu antibodies. Mice appear to show reactivity prior to clinical diagnosis of SCLC. This mouse model system will be useful to study SCLC-associated autoimmunity, its diagnostic value, and the potential protective role of oncoantigen-directed autoantibodies.
Introduction
Small-cell lung cancer (SCLC) accounts for up to 15% of all newly diagnosed lung cancers (Ries et al., 2007) . Initially, SCLC patients respond well to chemotherapy, but they inevitably relapse (Sandler, 2003) . Only 5% of patients are alive after five years (Worden and Kalemkerian, 2000) , making SCLC the most aggressive lung cancer subtype. There are currently no effective early detection methods for this disease.
Paraneoplastic encephalomyelitis/sensory neuronopathy (PEM/SN) is one of several rare autoimmune diseases associated with SCLC (Henson and Urich, 1982; Horwich et al., 1977) and occurs in less than 1% of SCLC patients (Anderson et al., 1987) . SCLC patients with PEM/SN harbor high titers of antibodies that react against neuronal Hu proteins (Dalmau et al., 1990 , 1991 Graus et al., 1986 Graus et al., , 2001 . Hu proteins are a family of four RNA-binding proteins, three of which are normally expressed in the nervous system (Good, 1995) . In SCLC, however, they are abnormally expressed in all tumors and act as onconeuronal antigens. Through an unknown mechanism, the immune system identifies them as foreign, generating anti-Hu autoantibodies. It is thought that these antibodies may be the result of a complex immune response that may react with Hu proteins in the healthy nervous system, leading to PEM/SN (Graus et al., 1985; Posner and Dalmau, 1997) . There is evidence to suggest that PEM/SN is mediated by a cytotoxic T-cell response against Hu proteins (Dalmau and Posner, 1994; Voltz et al., 1998) ; however, the mechanism coupling the immune response (humoral, T-cell mediated, or both) to the pathogenesis of the autoimmune disease remains in question.
Approximately 16% of SCLC patients without PEM/SN have detectable levels of anti-Hu antibody in their blood, albeit at much lower titers than PEM/SN patients (Dalmau et al., 1990; Graus et al., 1997) . It has been reported that the presence of even low levels of anti-Hu autoantibodies correlates with more indolent tumor growth (Dalmau et al., 1992; Graus et al., 1997) , suggesting that these antibodies might be protective. Interestingly, symptoms of PEM/SN often antedate tumor detection (Darnell and Posner, 2003) . If the antibody response were to arise when the cancer is still very small, it might be of use for SCLC early detection.
Studies of the origin and timing of anti-Hu response in SCLC patients are important, but the rapid progression of SCLC and relatively uncommon anti-Hu response makes such analyses in human patients difficult. A mouse model for SCLC and associated autoimmune diseases would therefore be very valuable. A unique SCLC mouse model system has recently been established based on the high frequency inactivation of tumor suppressor genes p53 and Rb in human SCLC (Meuwissen et al., 2003) . In this mouse model, both copies of p53 and Rb are homozygously floxed and conditionally inactivated in the lungs of 6-8 week old animals by intratracheal instillation of adenovirus carrying Cre recombinase (Adeno-Cre). SCLC tumors in these mice become detectable after 6-12 months (Meuwissen et al., 2003) . The anti-Hu response has not been investigated in this model system. 
